Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential
I'm PortAI, I can summarize articles.
Charles Zhu from LifeSci Capital has maintained a Buy rating on Compass Therapeutics, raising the price target to $12.00. This decision is based on the company's advancing clinical pipeline, including a third clinical response to CTX-8371 in Hodgkin lymphoma. Upcoming data from the COMPANION-002 study, scheduled for late Q1 2026, is seen as a key catalyst. Zhu emphasizes the clear roadmap for 2026 and believes the current valuation presents an attractive risk-reward profile for investors. Canaccord Genuity also supports a Buy rating with a $10.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments